These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26495746)

  • 21. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
    Roberts LS; Yan P; Bateman LA; Nomura DK
    ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
    Moore-Smith L; Forero-Torres A; Stringer-Reasor E
    Surg Clin North Am; 2018 Aug; 98(4):773-785. PubMed ID: 30005773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
    Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
    Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple negative breast cancer.
    Cetin I; Topcul M
    Asian Pac J Cancer Prev; 2014; 15(6):2427-31. PubMed ID: 24761842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.
    Carbognin L; Furlanetto J; Vicentini C; Nortilli R; Pilotto S; Brunelli M; Pellini F; Pollini GP; Bria E; Tortora G
    Anticancer Agents Med Chem; 2015; 15(1):15-25. PubMed ID: 25329488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-microsecond pulsed curcumin for effective treatment of triple negative breast cancers.
    Mittal L; Raman V; Camarillo IG; Sundararajan R
    Biochem Biophys Res Commun; 2017 Sep; 491(4):1015-1020. PubMed ID: 28780353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
    Su S; Tian Y; Li Y; Ding Y; Ji T; Wu M; Wu Y; Nie G
    ACS Nano; 2015 Feb; 9(2):1367-78. PubMed ID: 25611071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics.
    Hu Y
    Curr Top Med Chem; 2017; 17(20):2233-2234. PubMed ID: 28799501
    [No Abstract]   [Full Text] [Related]  

  • 34. A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer.
    Ouyang L; Zhang L; Fu L; Liu B
    Autophagy; 2017 Apr; 13(4):777-778. PubMed ID: 28165887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of CXC chemokines and their receptors in cancer.
    Vinader V; Afarinkia K
    Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces.
    Kim J; Kim H; Park SB
    J Am Chem Soc; 2014 Oct; 136(42):14629-38. PubMed ID: 25310802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
    Agrawal LS; Mayer IA
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological inhibitors of autophagy as novel cancer therapeutic agents.
    Wang C; Hu Q; Shen HM
    Pharmacol Res; 2016 Mar; 105():164-75. PubMed ID: 26826398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.